WO2009057111A3 - Précurseurs neuraux dérivés de cellules souches humaines pour le traitement de maladies auto-immunes du système nerveux central - Google Patents

Précurseurs neuraux dérivés de cellules souches humaines pour le traitement de maladies auto-immunes du système nerveux central Download PDF

Info

Publication number
WO2009057111A3
WO2009057111A3 PCT/IL2008/001426 IL2008001426W WO2009057111A3 WO 2009057111 A3 WO2009057111 A3 WO 2009057111A3 IL 2008001426 W IL2008001426 W IL 2008001426W WO 2009057111 A3 WO2009057111 A3 WO 2009057111A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
treatment
autoimmune diseases
stem cell
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2008/001426
Other languages
English (en)
Other versions
WO2009057111A2 (fr
Inventor
Michal Aharonowiz
Ofira Einstein
Benjamin Reubinoff
Tamir Ben-Hur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Original Assignee
Hadasit Medical Research Services and Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co filed Critical Hadasit Medical Research Services and Development Co
Priority to US12/740,496 priority Critical patent/US9862925B2/en
Priority to EP08845237A priority patent/EP2217252A2/fr
Publication of WO2009057111A2 publication Critical patent/WO2009057111A2/fr
Anticipated expiration legal-status Critical
Publication of WO2009057111A3 publication Critical patent/WO2009057111A3/fr
Priority to US15/826,235 priority patent/US20180080007A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation d'une population de cellules contenant : (a) des cellules neurales précurseurs prédestinées à un développement oligodendroglial; (b) des cellules neurales précurseurs non prédestinées (c) des oligodendrocytes différenciés; ou (d) une combinaison de cellules appartenant à (a), (b) ou (c), pour le traitement de maladies auto-immunes du SNC, ou pour la préparation d'une composition pharmaceutique destinée à traiter des maladies auto-immunes du SNC, la population de cellules étant dérivée de cellules souches humaines pluripotentes. L'invention concerne également des procédés permettant d'obtenir de telles populations de cellules, à savoir des cellules neurales précurseurs prédestinées à un développement oligodendroglial ainsi que des oligodendrocytes différenciés qui peuvent ensuite être utilisés pour le traitement de maladies auto-immunes du SNC. Dans le cadre de la présente invention, une maladie auto-immune préférée est la sclérose en plaques dont le traitement local est réalisé par une administration de la population de cellules au SNV.
PCT/IL2008/001426 2007-10-29 2008-10-29 Précurseurs neuraux dérivés de cellules souches humaines pour le traitement de maladies auto-immunes du système nerveux central Ceased WO2009057111A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/740,496 US9862925B2 (en) 2007-10-29 2008-10-29 Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system
EP08845237A EP2217252A2 (fr) 2007-10-29 2008-10-29 Précurseurs neuraux dérivés de cellules souches humaines pour le traitement de maladies auto-immunes du système nerveux central
US15/826,235 US20180080007A1 (en) 2007-10-29 2017-11-29 Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74607P 2007-10-29 2007-10-29
US61/000,746 2007-10-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/740,496 A-371-Of-International US9862925B2 (en) 2007-10-29 2008-10-29 Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system
US15/826,235 Continuation US20180080007A1 (en) 2007-10-29 2017-11-29 Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system

Publications (2)

Publication Number Publication Date
WO2009057111A2 WO2009057111A2 (fr) 2009-05-07
WO2009057111A3 true WO2009057111A3 (fr) 2010-05-27

Family

ID=40591589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/001426 Ceased WO2009057111A2 (fr) 2007-10-29 2008-10-29 Précurseurs neuraux dérivés de cellules souches humaines pour le traitement de maladies auto-immunes du système nerveux central

Country Status (3)

Country Link
US (2) US9862925B2 (fr)
EP (1) EP2217252A2 (fr)
WO (1) WO2009057111A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153424B2 (en) * 2001-10-03 2012-04-10 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
CA2556266A1 (fr) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Utilisation de l'hormone de luteinisation (lh) et de la gonadotropine chorionique (hcg) pour la proliferation de cellules souches neuronales et la neurogenese
EP2593117B1 (fr) 2010-07-12 2019-03-20 University of Southern California Substrat biocompatible destiné à faciliter les interconnexions entres les cellules souches et les tissus cibles et procédés d'implantation associés
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
WO2015124725A1 (fr) * 2014-02-21 2015-08-27 Johan Ericson Types de cellules du système nerveux central tardives
WO2017173064A1 (fr) * 2016-03-30 2017-10-05 Asterias Biotherapeutics, Inc. Compositions de cellules progénitrices d'oligodendrocytes
US12365872B2 (en) 2018-09-19 2025-07-22 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
KR20260020476A (ko) 2019-01-23 2026-02-11 아스테리아스 바이오세라퓨틱스, 인크. 인간 만능 줄기 세포로부터의 배측-유래된 희소돌기아교세포 전구 세포
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
KR20220158046A (ko) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. 신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
WO2022036150A1 (fr) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Méthodes de traitement de patients sensibilisés avec des cellules hypo-immunogènes, ainsi que méthodes et compositions associés
US20240226164A1 (en) 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
EP4384598A1 (fr) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Cellules génétiquement modifiées pour une thérapie cellulaire allogénique pour réduire les réactions inflammatoires induites par le complément
AU2022327174A1 (en) 2021-08-11 2024-02-15 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
US20240358761A1 (en) 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
WO2023183313A1 (fr) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Cellules d'ingénierie avec un transgène dans un locus b2m ou ciita et compositions et procédés associés
WO2025054202A1 (fr) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Procédé de criblage d'un échantillon contenant un transgène à l'aide d'un code à barres unique
WO2025151838A1 (fr) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Commutateurs de sécurité pour réguler la prolifération in vitro et in vivo de produits de thérapie cellulaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059072A1 (fr) * 2000-02-11 2001-08-16 Philadelphia Health And Education Corporation Differentiation des cellules stromales de la moelle osseuse en cellules neuronales et utilisation associee

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588937B2 (en) * 2001-10-03 2009-09-15 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US7799324B2 (en) * 2001-12-07 2010-09-21 Geron Corporation Using undifferentiated embryonic stem cells to control the immune system
EP1684706A4 (fr) * 2003-11-10 2008-01-09 Cornell Res Foundation Inc Genes exprimes de maniere differentielle par des cellules precurseurs residentes isolees de matiere blanche humaine
JP5559680B2 (ja) * 2007-06-27 2014-07-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 神経幹細胞

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059072A1 (fr) * 2000-02-11 2001-08-16 Philadelphia Health And Education Corporation Differentiation des cellules stromales de la moelle osseuse en cellules neuronales et utilisation associee

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
HALFPENNY C ET AL: "Cell transplantation, myelin repair, and multiple sclerosis", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 1, no. 1, 1 May 2002 (2002-05-01), pages 31 - 40, XP004814214, ISSN: 1474-4422 *
JOANNIDES ET AL: "Human embryonic stem cells: An experimental and therapeutic resource for neurological disease", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 265, no. 1-2, 24 October 2007 (2007-10-24), pages 84 - 88, XP022419430, ISSN: 0022-510X *
KIM S U ET AL: "Stem cell-based cell therapy in neurological diseases: A review", JOURNAL OF NEUROSCIENCE RESEARCH 20090801 WILEY-LISS INC. USA, vol. 87, no. 10, 1 August 2009 (2009-08-01), pages 2183 - 2200, XP002561476, ISSN: 0360-4012 1097-4547 *
MILLER ET AL: "The promise of stem cells for neural repair", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1091, no. 1, 26 May 2006 (2006-05-26), pages 258 - 264, XP025064838, ISSN: 0006-8993, [retrieved on 20060526] *
OSTENFELD T ET AL: "RECENT ADVANCES IN STEM CELL NEUROBIOLOGY", ADVANCES AND TECHNICAL STANDARDS IN NEUROSURGERY, SPRINGER VERLAG, NEW YORK, NY, US, vol. 28, 1 January 2003 (2003-01-01), pages 3 - 89, XP009009717, ISSN: 0095-4829 *
PLUCHINO S ET AL: "The therapeutic use of stem cells for myelin repair in autoimmune demyelinating disorders", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 233, no. 1-2, 15 June 2005 (2005-06-15), pages 117 - 119, XP004932290, ISSN: 0022-510X *
RICE ET AL: "Cell Therapy in Demyelinating Diseases", JOURNAL OF THE AMERICAN SOCIETY FOR EXPERIMENTALNEUROTHERAPEUTICS, XX, XX, vol. 1, no. 4, 1 October 2004 (2004-10-01), pages 415 - 423, XP005871829, ISSN: 1545-5343 *
See also references of EP2217252A2 *
SILANI ET AL: "Stem cell transplantation in Multiple Sclerosis: Safety and Ethics", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 265, no. 1-2, 9 July 2007 (2007-07-09), pages 116 - 121, XP022419437, ISSN: 0022-510X *
UCCELLI A ET AL: "Stem cells for multiple sclerosis: Promises and reality", REGENERATIVE MEDICINE 200701 GB, vol. 2, no. 1, January 2007 (2007-01-01), pages 7 - 9, XP002561477, ISSN: 1746-0751 *

Also Published As

Publication number Publication date
US20180080007A1 (en) 2018-03-22
US9862925B2 (en) 2018-01-09
WO2009057111A2 (fr) 2009-05-07
EP2217252A2 (fr) 2010-08-18
US20110189135A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2009057111A3 (fr) Précurseurs neuraux dérivés de cellules souches humaines pour le traitement de maladies auto-immunes du système nerveux central
Forostyak et al. The role of mesenchymal stromal cells in spinal cord injury, regenerative medicine and possible clinical applications
Golas et al. Use of human stem cells in Huntington disease modeling and translational research
GB2452186A (en) Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
Dey et al. Symphytum officinale augments osteogenesis in human bone marrow-derived mesenchymal stem cells in vitro as they differentiate into osteoblasts
WO2008157791A3 (fr) Procédés et compositions pour stimuler la neurogenèse et inhiber une dégénérescence neuronale à l'aide d'isothiazolopyrimidinones
Huang et al. Directing adult human periodontal ligament–derived stem cells to retinal fate
MX2010004614A (es) Composiciones para tratamiento del mal de parkinson.
WO2003055992A3 (fr) Methode permettant d'etablir une lignee de cellules souches hematopoietiques multipotentes humaines derivees du blastocyste
WO2003006950A3 (fr) Cellules de la lignee des cardiomyocytes produites a partir de cellules souches humaines pluripotentielles
WO2006044204A3 (fr) Progeniteurs neuronaux obtenus par culture de cellules souches embryonnaires humaines sans cellules nourricieres
WO2011130675A3 (fr) Neurones dopaminergiques obtenus par différenciation de cellules souches pluripotentes et leurs utilisations
WO2007024441A3 (fr) Compositions cellulaires enrichies destines a la combinaison de diverses populations cellulaires a base de cellules souches et de cellules progenitrices, leurs methodes d'utilisation, et methodes de mise en banque privee
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
NZ612888A (en) Treatment of inflammatory diseases using placental stem cells
NZ602618A (en) Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
IL186228A0 (en) Preparation of autologous haematopoietic stem cells, the methods of production, cryopreservation and use for therapy of traumatic diseases of the central nervous system
WO2012074561A3 (fr) Procédés et compositions pour le traitement des troubles anxieux, y compris l'état de stress post-traumatique (espt) et les troubles apparentés du système nerveux central (snc)
NZ623207A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
Bagheri et al. Conditioned media derived from mesenchymal stem cells induces apoptosis and decreases cell viability and proliferation in squamous carcinoma cell lines
JP2022130483A (ja) 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
Liu et al. Inhibition of class II histone deacetylase blocks proliferation and promotes neuronal differentiation of the embryonic rat neural progenitor cells
WO2009018587A3 (fr) Dérivation de cellules souches neurales à partir de cellules souches embryonnaires et procédés d'utilisation de celles-ci
WO2007035722A3 (fr) Methodes et compositions permettant de stimuler la neurogenese et d'inhiber la degenerescence neuronale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08845237

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008845237

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12740496

Country of ref document: US